Press release
B-cell Lymphoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Biegene, Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus Li
"B-cell Lymphoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the B-cell Lymphoma Market.
The B-cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the B-cell Lymphoma Pipeline Report: https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel B-cell Lymphoma treatment therapies with a considerable amount of success over the years.
• B-cell Lymphoma companies working in the treatment market are Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others, are developing therapies for the B-cell Lymphoma treatment
• Emerging B-cell Lymphoma therapies in the different phases of clinical trials are- VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others are expected to have a significant impact on the B-cell Lymphoma market in the coming years.
• In November 2024, Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage biotechnology company developing next-generation CAR T-cell therapies for solid tumors and hematologic cancers, announced that preliminary clinical data from the Phase 1-2 trial of IMPT-314 in large B-cell lymphoma will be featured at the 66th American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA, from December 7 to 10, 2024. The presentation will be delivered by Dr. Sarah M. Larson, Associate Professor of Medicine and Medical Director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at UCLA's David Geffen School of Medicine.
B-cell Lymphoma Overview
B-cell Lymphoma is a cancer originating from B cells, a crucial component of the immune system. This type of lymphoma can manifest as either slow-growing (indolent) or fast-growing (aggressive). Generally, most B-cell lymphomas belong to the category of non-Hodgkin lymphomas. Within this classification, there exist numerous diverse types of B-cell non-Hodgkin lymphomas.
Get a Free Sample PDF Report to know more about B-cell Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging B-cell Lymphoma Drugs Under Different Phases of Clinical Development Include:
• VIP 924: Vincerx Pharma
• UBX-303-1: Ubix Therapeutics
• BMF-219: Biomea Fusion Inc.
• SHR-A1912: Shanghai Hengrui Pharmaceutical
• Ociperlimab: BeiGene
• AUTO3: Autolus Limited
• GNC-038: SystImmune Inc
• Poseltinib: Hanmi Pharmaceutical
• Abexinostat: Xynomic Pharmaceuticals
• PF-07901801: Pfizer
• Odronextamab: ZAI Lab
• Zilovertamab: Oncternal Therapeutics
• PF-07901801: Pfizer
• LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.
• TG-1801: TG Therapeutics, Inc.
B-cell Lymphoma Route of Administration
B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
B-cell Lymphoma Molecule Type
B-cell Lymphoma Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
B-cell Lymphoma Pipeline Therapeutics Assessment
• B-cell Lymphoma Assessment by Product Type
• B-cell Lymphoma By Stage and Product Type
• B-cell Lymphoma Assessment by Route of Administration
• B-cell Lymphoma By Stage and Route of Administration
• B-cell Lymphoma Assessment by Molecule Type
• B-cell Lymphoma by Stage and Molecule Type
DelveInsight's B-cell Lymphoma Report covers around 170+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further B-cell Lymphoma product details are provided in the report. Download the B-cell Lymphoma pipeline report to learn more about the emerging B-cell Lymphoma therapies
https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the B-cell Lymphoma Therapeutics Market include:
Key companies developing therapies for B-cell Lymphoma are - Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, and others.
B-cell Lymphoma Pipeline Analysis:
The B-cell Lymphoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of B-cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-cell Lymphoma Treatment.
• B-cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• B-cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-cell Lymphoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about B-cell Lymphoma drugs and therapies
https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
B-cell Lymphoma Pipeline Market Drivers
• Increase in prevalence of B-cell Lymphoma, launch of several novel therapies for treating B cell Lymphoma are some of the important factors that are fueling the B-cell Lymphoma Market.
B-cell Lymphoma Pipeline Market Barriers
• However, high cost of the treatment, side effects associated with the therapies and other factors are creating obstacles in the B-cell Lymphoma Market growth.
Scope of B-cell Lymphoma Pipeline Drug Insight
• Coverage: Global
• Key B-cell Lymphoma Companies: Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others
• Key B-cell Lymphoma Therapies: VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others
• B-cell Lymphoma Therapeutic Assessment: B-cell Lymphoma current marketed and B-cell Lymphoma emerging therapies
• B-cell Lymphoma Market Dynamics: B-cell Lymphoma market drivers and B-cell Lymphoma market barriers
Request for Sample PDF Report for B-cell Lymphoma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. B-cell Lymphoma Report Introduction
2. B-cell Lymphoma Executive Summary
3. B-cell Lymphoma Overview
4. B-cell Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. B-cell Lymphoma Pipeline Therapeutics
6. B-cell Lymphoma Late Stage Products (Phase II/III)
7. B-cell Lymphoma Mid Stage Products (Phase II)
8. B-cell Lymphoma Early Stage Products (Phase I)
9. B-cell Lymphoma Preclinical Stage Products
10. B-cell Lymphoma Therapeutics Assessment
11. B-cell Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. B-cell Lymphoma Key Companies
14. B-cell Lymphoma Key Products
15. B-cell Lymphoma Unmet Needs
16 . B-cell Lymphoma Market Drivers and Barriers
17. B-cell Lymphoma Future Perspectives and Conclusion
18. B-cell Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
Latest Reports
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Interspinous Spacers Market: https://www.delveinsight.com/report-store/interspinous-spacers-market
• Dengue Fever Market: https://www.delveinsight.com/report-store/dengue-fever-market
• Chronic Hemodialysis Market: https://www.delveinsight.com/report-store/chronic-hemodialysis-market
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release B-cell Lymphoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Biegene, Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus Li here
News-ID: 3806710 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Lymphoma
Lymphoma Treatment Market - Liberating Lives from Lymphoma: State-of-the-Art Tre …
Newark, New Castle, USA: The "Lymphoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lymphoma Treatment Market: https://www.growthplusreports.com/report/lymphoma-treatment-market/8879
This latest report researches the industry structure, sales, revenue,…
Lymphoma Treatment Market - Inspiring Resilience, Shaping Survival: Innovations …
Newark, New Castle, USA - new report, titled Lymphoma Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Lymphoma Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Lymphoma Treatment market. The report offers an overview of the market, which…
Lymphoma Therapeutics Market: New Frontiers in Lymphoma Therapeutics | By AMR
Allied Market Research recently said Lymphoma is a type of cancer that affects the lymphatic system, which is an integral part of the body's immune system. While chemotherapy and radiation therapy have been the standard treatment options for lymphoma, recent advances in research have led to the development of new targeted therapies and immunotherapies.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-toc-and-sample/1448
One such targeted therapy is monoclonal antibodies, which can specifically target…
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…
